ArticleScientific reports2022

A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.

Sondra L Downey-Kopyscinski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.